Evidence map›Paper›PMID 31393358›Full record

ArticleMedicine2019

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports.

Chen Chen, Song-Ran Liu, Shu Zhou, Xiao-Hui Li, Xiao-Hui Wang, Ya-Lan Tao, Hui Chang, Wen-Wen Zhang, Wen-Fei Li, Si-Lang Zhou and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chen ChenDepartment of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China.
Song-Ran Liu
Shu Zhou
Xiao-Hui Li
Xiao-Hui Wang
Ya-Lan Tao
Hui Chang
Wen-Wen Zhang
Wen-Fei Li
Si-Lang Zhou
Yun-Fei Xia

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleRefractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. PATIENT CONCERNS: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. DIAGNOSIS: They were diagnosed as refractory nasopharyngeal carcinoma.

interventionsA continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. OUTCOMES: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load. LESSONS: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.

Indexed as

AdultAngiogenesis InhibitorsChemoradiotherapyEndostatinsFemaleHumansInfusions, IntravenousMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsRecombinant ProteinsAngiogenesis Inhibitorsendostar proteinEndostatinsRecombinant Proteins

Identifiers

PMID31393358
PMCPMC6709293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.